Nonmelanoma skin cancer in the Federal State of Saarland, Germany, 1995–1999 by Stang, A et al.
Short Communication
Nonmelanoma skin cancer in the Federal State of Saarland,
Germany, 1995–1999
A Stang*,1, C Stegmaier
2 and K-H Jo ¨ckel
1
1Epidemiology Unit, Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, Hufelandstr. 55, 45122 Essen, Germany;
2Saarland Cancer Registry, Saabru ¨cken, Germany
We analysed incidence data of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin from the Cancer Registry
Saarland, Germany. During 1995–1999, the age-standardised incidence rates (world standard population) of BCC and SCC were
43.7 and 11.2 per 100000 among men and 31.7 and 4.4 per 100000 among women.
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Nonmelanoma skin cancer (NMSC) is one of the most common
malignant neoplasms in Caucasian populations around the world,
and usually refers to either basal cell carcinoma (BCC) or
squamous cell carcinoma (SCC) (Weinstock, 1994). Epidemiologic
studies of these tumours have been limited by the fact that most
patients are customarily seen and treated in the offices of
physicians and not hospitalised (Scotto et al, 1983). Since the
primary source of data for cancer registries is the in-patient
hospital file, routinely collected statistics on NMSC are usually
incomplete and not comparable with other forms of cancer (Scotto
et al, 1996; Lucke et al, 1997). In addition, many cancer registries
do not collect information on BCC and the incidence is often
determined on the basis of surveys (e.g. Fears and Scotto, 1982;
Giles et al, 1988; Green and Battistutta, 1990; Kricker et al, 1990;
Roberts, 1990; Serrano et al, 1991; Green et al, 1996). In a recent
review on the epidemiology of NMSC incidence, Green concluded
that ‘little is known about worldwide trends in incidence of BCC
and SCC’ (Green, 1992).
Here, we present the findings of detailed analyses of the NMSC
incidence of the Federal State of Saarland for the period 1995–
1999. We also report the incidence by histological groups and
anatomical sites.
After the introduction of the International Classification of
Disease for Oncology (ICD-O, first edition, WHO) in 1976, the
population-based Saarland Cancer Registry (about 1.1 million
residents) gradually used this classification to code NMSC reports.
Due to the large number of NMSC reports and the limited number
of registry staff, the majority of NMSC reports until 1994 were
either only coded by the International Classification of Diseases,
9th revision (WHO, 1976), coded as unspecified skin cancer
according to ICD-O (M800, M997), or coded by a histology
variable that indicates whether the NMSC was a BCC, SCC or other
skin cancer.
For the period 1995–1999, we checked all NMSC reports that
either showed a mismatch between the histology variable and
ICDO code, were coded as histologies that are usually not observed
in the skin (e.g. leiomyosarcoma) or that were coded as lesions that
do not belong to the group of NMSC (e.g. skin melanoma). Of the
6831 reports during this period, about 133 (2%) were checked.
Seven of the 133 cancers were reclassified as other cancers or
benign tumours, six out of 55 SCCs of the 133 reports were
reclassified as BCCs and two out of 44 BCC reports were
reclassified as SCCs.
After the data cleaning of the reports, we classified all reports
according to the recommendations of the European Network of
Cancer Registries (2000) on the classification of NMSCs based on
the ICD-O third edition (BCC: M809–M811; SCC: M805–M808,
M812–M813; and other or unspecified tumours). NMSC reports
with missing ICD-O code were classified according to the histology
variable of the cancer registry if this variable was nonmissing.
For the first occurrence of BCC and SCC, we restricted the
calculation of incidence rates to the period 1995–1999 because
before 1995, the annual proportion of unspecified histology codes
was too large (410%). Basal cell carcinoma and SCC counted only
if the patient had no prior registered cancer with the same
histologic diagnosis. Patients with a report both of BCC and SCC
during the registration period were counted as cases within the
BCC and SCC analysis.
We calculated site-specific incidence rates based on the fourth
digit of the ICD-9 code (ICD-9: 173.0 skin of the lip, 173.1 eyelid,
173.2 external ear, 173.3 skin of other and unspecified parts of face,
173.4 skin of the scalp and neck, 173.5 skin of the trunk, 173.6 skin
of the upper limb and shoulder, 173.7 skin of the lower limb and hip,
173.8 overlapping lesions of skin, 173.9 skin, not other specified).
We calculated sex-specific age-standardised incidence rates for
BCC and SCC using the World Standard Population (Parkin et al,
1992) for the period 1995–1999. We also calculated age-specific
incidence rates. For the study of the anatomical distribution of
BCC and SCC, we calculated relative site-specific age-standardised
incidence rates per unit area of the skin (RSA) for the period
1995–1999. We therefore divided the site-specific age-standar- Received 16 May 2003; revised 5 August 2003; accepted 5 August 2003
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ydised incidence rates by the proportion of surface area of the
corresponding body sites based on the estimates of the propor-
tional surface area from Elwood and Gallagher (1998): face 2.3%,
ear 0.5%, scalp and neck 6.1%, trunk 32%, arms and hands 16.5%,
legs 40%. We estimated the proportional surface area of the lips
(0.1%) and the eye lids (0.5%). We performed all analyses with SAS
(SAS Inst., 1999).
Tables 1 and 2 present age-specific, crude and age-standardised
incidence rates of first BCC and SCC among men and women from
1995 to 1999. Men had a 38% (95% CI: 27–50%) higher age-
standardised incidence rate of BCC and a 55% (95% CI: 18–98%)
higher age-standardised incidence of SCC than women. The
median age at which a first BCC occurred was 68 years in men
and 71 years in women, while that for first SCC was 74 years in
men and 80 years in women.
The site-specific analyses of the age-standardised incidence rates
of first BCCs and SCCs are presented in Tables 3 and 4. The risks of
BCCs at the ears and the arms are higher for men than women. The
risks of SCCs of the ears and scalp or neck are 15- and 7.6-fold
higher among men than women. Although based on small
numbers, the risk of SCCs at the lips appears to be 5.3-fold higher
among men than women.
The comparison of the incidence rates by anatomic site is
complicated because the anatomic sites have different surface
areas. The site-specific age-standardised incidence rates for first
BCCs and SCCs per unit area of the skin (RSA) correct for the
different sizes of the surface areas. The comparison of the RSAs
reveals that the risk of BCCs is highest at the eye lids, face and
lips among both men and women. The risk of SCCs is highest at
the lips, ears and face among men and lips, face and eye lids
among women.
Nonmelanoma skin cancer results in relevant morbidity and
mortality. This article provides population-based incidence
estimates of BCC and SCC in West Germany. The incidence
estimates of first occurrence are well comparable with the rates in
other countries, including Denmark 1978–1982 (Osterlind et al,
1988), Finland 1991–1995 (Hannuksela-Svahn et al, 1999) and the
Netherlands 1988 (Coebergh et al, 1991), but less than half of the
rates in Australia (Buettner and Raasch, 1998).
Due to the large number of NMSC that were not coded
according to the ICD-O before 1995 in the Saarland Cancer
Registry, we were not able to analyse incidence time trends
separately for BCC and SCC over a long period. The rising
incidence of NMSC in the United States during the 1970s
mainly affected BCC (Fears and Scotto, 1982). The age-adjusted
incidence rate of SCCs in Arizona, USA, declined from 1985 to
1996 (Harris et al, 2001). Gallagher et al (1990) found similar
incidence increases of BCC and SCC in British Columbia, Canada,
from 1973 to 1987. These increases were most pronounced in the
head and neck area. Levi et al (2001) observed an incidence
increase of SCC and BCC in the Swiss Canton of Neuchatel from
1976 to 1998.
Body-site-specific incidence rates of both BCC and SCC showed
wide variation with a clear preference for sun-exposed sites. The
predilection of BCCs and SCCs for the head has been described
previously (Pearl and Scott, 1986; Osterlind et al, 1988; Gallagher
et al, 1990; Chuang et al, 1990a,b; Coebergh et al, 1991; Serrano
et al, 1991; Buettner and Raasch, 1998; Harris et al, 2001). The
higher risk of NMSC of the ear, scalp and neck in men than women
may be explained by the hairstyle among men, which less often
covers these sites than among women. The excess risk of NMSC at
the ears among men, which was also observed in Finland and the
Netherlands (Coebergh et al, 1991; Hannuksela-Svahn et al, 1999),
was mainly due to an excess risk of SCCs of the ears in our data.
Smoking increases the risk of SCCs of the lip (Scotto et al, 1996; De
Hertog et al, 2001) and may explain the higher risk of SCCs of the
lips among men than women in our and other analyses (Coebergh
et al, 1991; Buettner and Raasch, 1998). The risk of BCC of the legs
among women is higher than among men, which has been also
observed for skin melanoma and may correspond to the larger
amount of sunlight exposure at the legs among women than men
(Gallagher et al, 1990; Stang et al, 2003).
The public health problem of NMSC is several-fold. Incident
cases of NMSC appear to be alarmingly common and increasing in
frequency, even in young adulthood. They cause a considerable
burden of morbidity, particularly deformity, as well as expense.
Although death among NMSC cases is the exception rather than
the rule, it also presents a considerable burden.
A limitation of our study results is the potential underestimation
of the incidence rates due to incomplete registration of NMSCs
that has been found by other cancer registries (Lucke et al, 1997;
Hannuksela-Svahn et al, 1999; Maudsley and Williams, 1999).
Unlike most other epithelial cancers, a large proportion of NMSC
Table 1 Age-specific, crude and age-standardised incidence rates of
BCC and SCC among men in the Federal State of Saarland, 1995–1999
BCC SCC
Age (years) N Rate s.e. N Rate s.e.
30–34 12 5.2 1.49 0 0.0 0.00
35–39 22 9.5 2.02 5 2.2 0.96
40–44 47 22.2 3.24 5 2.4 1.06
45–49 82 43.3 4.78 9 4.8 1.58
50–54 110 73.6 7.02 7 4.7 1.77
55–59 198 104.6 7.44 30 15.9 2.89
60–64 281 165.3 9.86 50 29.4 4.16
65–69 335 244.1 13.34 66 48.1 5.92
70–74 348 344.9 18.49 119 117.9 10.81
75–79 259 453.2 28.16 100 175.0 17.50
80–84 137 455.2 38.89 90 299.1 31.52
85+ 116 565.6 52.51 62 302.3 38.39
All ages
Crude 1960 74.9 1.69 543 20.8 0.89
WSR 1960 43.7 1.17 543 11.2 0.49
Rate: cases per 100000; s.e.¼standard error of the rate; crude¼crude rate;
WSR¼age-standardised rate (World Standard Population); BCC¼basal cell
carcinoma; SCC¼squamous cell carcinoma.
Table 2 Age-specific, crude and age-standardised incidence rates of
BCC and SCC among women in the Federal State of Saarland, 1995–1999
BCC SCC
Age (years) N Rate s.e. N Rate s.e.
30–34 26 11.7 2.30 0 0.0 0.00
35–39 34 15.4 2.64 0 0.0 0.00
40–44 53 26.3 3.61 4 2.0 0.99
45–49 79 43.8 4.93 1 0.6 0.56
50–54 88 59.8 6.38 5 3.4 1.52
55–59 178 91.2 6.83 17 8.7 2.11
60–64 224 123.9 8.28 24 13.3 2.71
65–69 243 153.0 9.81 23 14.5 3.02
70–74 287 179.1 10.57 50 31.2 4.41
75–79 305 267.8 15.34 72 63.2 7.45
80–84 253 331.5 20.84 83 108.7 11.94
85+ 199 274.2 19.43 140 192.9 16.30
All ages
Crude 1977 71.1 1.60 420 15.1 0.74
WSR 1977 31.7 1.06 420 4.4 0.31
Rate¼cases per 100000; s.e.¼standard error of the rate; crude¼crude rate;
WSR¼age-standardised rate (World Standard Population); BCC¼basal cell
carcinoma; SCC¼squamous cell carcinoma.
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yare easily treated by physicians (e.g. by cryotherapy, currettage,
diathermy or excision) without histological confirmation of the
diagnosis (Green, 1992) hampering the population-based registra-
tion of these tumours via pathology departments by the cancer
registry. In addition, a variable proportion of people with skin
cancer never present for medical treatment because of lack of
symptoms or low levels of medical or public interest and such
cases will escape conventional means of detection altogether. On
the other hand, new cases of skin cancers, especially SCCs, may not
be recognised or correctly diagnosed on presentation to doctors.
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